PURPOSE: In spite of the recent advances in surgery and antitumor drugs, the brain tumors, like glioblastoma, have shown a poor prognosis. The aim of this study was to determine the effect of pertussis toxin (PTx) as immunomodulatory molecule on glial tumors induced by C6 glioma cells. METHODS: Given the pleiotropic effect of PTx on the immune system, we analyzed the effect of PTx on CD4+/CD25+/FoxP3+ (Treg) cells like as immunotherapeutic adjuvant. Thirty rats with a glial tumor of 1.5 cm in diameter were separated in two groups: the first group was treated with PTx and the second group was non-treated (controls). Tumoral volume was measured weekly; tumor, blood and spleen were taken for analysis of subpopulations of T cells, apoptotic index and cytokine contents, in both groups. RESULTS: We observed a significant decrease in tumor volume in the PTx group; this was associated with a decreased in the number of Treg cells, in both spleen and tumor. The percentage of apoptotic cells was increased as compared with that of controls. The production of proinflammatory cytokines was increased in mRNA for IL-6 as well as a small increase in the mRNA expression of perforin and granzime in tumors from rats treated with PTx. No changes were found in the mRNA expression of MCP-1 and MIP-1α. CONCLUSION: These results suggest that PTx could be an immunotherapeutic adjuvant in the integral therapy against glial tumors.
PURPOSE: In spite of the recent advances in surgery and antitumor drugs, the brain tumors, like glioblastoma, have shown a poor prognosis. The aim of this study was to determine the effect of pertussis toxin (PTx) as immunomodulatory molecule on glial tumors induced by C6 glioma cells. METHODS: Given the pleiotropic effect of PTx on the immune system, we analyzed the effect of PTx on CD4+/CD25+/FoxP3+ (Treg) cells like as immunotherapeutic adjuvant. Thirty rats with a glial tumor of 1.5 cm in diameter were separated in two groups: the first group was treated with PTx and the second group was non-treated (controls). Tumoral volume was measured weekly; tumor, blood and spleen were taken for analysis of subpopulations of T cells, apoptotic index and cytokine contents, in both groups. RESULTS: We observed a significant decrease in tumor volume in the PTx group; this was associated with a decreased in the number of Treg cells, in both spleen and tumor. The percentage of apoptotic cells was increased as compared with that of controls. The production of proinflammatory cytokines was increased in mRNA for IL-6 as well as a small increase in the mRNA expression of perforin and granzime in tumors from rats treated with PTx. No changes were found in the mRNA expression of MCP-1 and MIP-1α. CONCLUSION: These results suggest that PTx could be an immunotherapeutic adjuvant in the integral therapy against glial tumors.
Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440
Authors: Xin Chen; Robin T Winkler-Pickett; Nicholas H Carbonetti; John R Ortaldo; Joost J Oppenheim; O M Zack Howard Journal: Eur J Immunol Date: 2006-03 Impact factor: 5.532
Authors: Andrew S Gilder; Lei Wang; Letizia Natali; Nicki Karimi-Mostowfi; Coralie Brifault; Steven L Gonias Journal: PLoS One Date: 2016-12-15 Impact factor: 3.240
Authors: Marisol Orozco-Ibarra; Jorge Muñoz-Sánchez; Martín E Zavala-Medina; Benjamín Pineda; Roxana Magaña-Maldonado; Edgar Vázquez-Contreras; Perla D Maldonado; José Pedraza-Chaverri; María Elena Chánez-Cárdenas Journal: Biol Res Date: 2016-02-01 Impact factor: 5.612
Authors: Anna Gieryng; Dominika Pszczolkowska; Katarzyna Bocian; Michal Dabrowski; Wenson David Rajan; Michal Kloss; Jakub Mieczkowski; Bozena Kaminska Journal: Sci Rep Date: 2017-12-14 Impact factor: 4.379